< Back to press releases
eRelevance Corporation Completes its First Dozen Customer Installs
Customers are represented across multiple healthcare practices.
AUSTIN, Texas – June 24, 2014 — eRelevance Corporation (www.erelevancecorp.com), a progressive Health IT services company, announced today that it has hit its first quarter target by acquiring and launching its first dozen customers represented by dental, dermatology, OB/GYN, optometry, and plastic surgery practices.
“The eRelevance service uniquely communicates with patients in a personalized and automated way that has helped us activate some of our inactive patients,” stated Dr. Daren Evans, DDS. “In just the first month the service paid for itself for nearly the whole year.”
“We’ve been pleased with the early adoption of our progressive patient engagement service,” stated Bob Fabbio, co-founder and CEO of eRelevance Corporation. “Within just a few months we have been able to show value to every customer across all of the various healthcare practices and there are now more than 20,000 patients that have access to our platform.”
eRelevance offers a SERVICE to healthcare practices and hospital systems that targets and engages patients in automated, personalized two-way dynamic DIALOGS. The service leverages industry leading, HIPAA-compliant, cloud-based technology to educate, assess health, discover needs, cultivate interests, offer promotions, and learn about the patient’s life. As a service, no labor burden is placed on the providers or their staff!
About eRelevance Corporation
eRelevance Corporation offers a Progressive Patient Engagement Service that gives healthcare providers an automated ability to build better relationships with their existing and prospective patients outside the point-of-care that puts no burden on the providers or their staff. The service leverages industry leading technology to improve patient relationships, increase revenue, and reduce staff workload. The company, located in Austin, Texas was founded in 2013 by Robert Fabbio, Lance Obermeyer, and Timothy Smith.